Actively Recruiting
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2024-11-15
30
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
CONDITIONS
Official Title
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of any gender, aged between 18 and 75 years (inclusive)
- Positive expression of CD123 on tumor cells detected by flow cytometry
- Confirmed diagnosis of CD123-positive relapsed/refractory AML or BPDCN
- Expected survival time of more than 12 weeks
- ECOG performance status score of 0 to 2
- No severe mental disorders
- Basic normal function of important organs including blood counts, heart, kidney, liver, and blood oxygen saturation
- Patient or legal guardian agrees to participate and signs informed consent form
You will not qualify if you...
- Active central nervous system invasion during screening
- Anti-tumor treatments within 14 days or at least 5 half-lives before screening, except if disease progression is confirmed
- Cerebrovascular accident or epileptic seizure within 6 months prior to screening
- Active or uncontrolled infection requiring treatment within 1 week prior to screening
- Severe cardiac diseases including congestive heart failure (NYHA class III or IV), recent myocardial infarction or coronary artery surgery, significant arrhythmias, or severe cardiomyopathy
- Active autoimmune diseases requiring long-term immunosuppressive therapy
- Other malignancies except certain treated cancers
- Live attenuated vaccines within 4 weeks prior to screening
- Pregnant or breastfeeding women, or subjects planning to have children within 1 year after CAR-NK infusion
- Any other condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
W
Wei Jia, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here